1. Search Result
Search Result
Results for "

hyperglycemic

" in MCE Product Catalog:

18

Inhibitors & Agonists

7

Natural
Products

Cat. No. Product Name Target Research Areas
  • HY-P0005
    Glucagon (Human)

    Glukagon; hyperglycemic-glycogenolytic factor

    Others Metabolic Disease
    Glucagon exhibits marked effects on protein and amino acid metabolism. Glucagon inhibits the incorporation of amino acids into protein of liver, muscle, and pancreas, to increase excretion of nitrogen, to promote hepatic urea synthesis, and to increase the concentration of hepatic transaminases and urea cycle enzymes. Glucagon can promote the hepatic uptake of amino acids, to enhance their incorporation into liver glycogen, and to depress the concentration of amino acids in blood.
  • HY-146128
    Anti-hyperglycemic agent-1

    Glucosidase Metabolic Disease
    Anti-hyperglycemic agent-1 (compound 10) is a potent α-Glucosidase inhibitor, with an IC50 of 0.53 μM. Anti-hyperglycemic agent-1 can be used for diabetes research.
  • HY-D0020
    2,2'-Bipyridine

    Others Infection Endocrinology
    2,2'-Bipyridine is the unique molecular scaffold of the bioactive natural products. 2,2'-Bipyridine is extensively used as the core structure of many chelating ligands by acting as a bridge in the arrangement of the catalytic center. 2,2'-Bipyridine shows robust redox stability and hyperglycemic activity.
  • HY-N0807
    Swertiamarin

    Others Metabolic Disease Cancer
    Swertiamarin, a secoiridoid glycoside found in genera of Enicostemma Species, confers anti-hyperglycemic and anti-hyperlipidemic effects.
  • HY-N0547
    Nomilin

    Others Metabolic Disease
    Nomilin is a limonoid compound obtained from the extracts of citrus fruits. Nomilin is an anti-obesity and anti-hyperglycemic agent .
  • HY-N0472
    Geraniin

    TNF Receptor Cancer Metabolic Disease Inflammation/Immunology
    Geraniin is a TNF-α releasing inhibitor with numerous activities including anticancer, anti-inflammatory, and anti-hyperglycemic activities, with an IC50 of 43 μM.
  • HY-133127
    AR453588

    Glucokinase Metabolic Disease
    AR453588 is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC50 of 42 nM. AR453588 shows anti-hyperglycemic activity.
  • HY-133127A
    AR453588 hydrochloride

    Glucokinase Metabolic Disease
    AR453588 hydrochloride is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC50 of 42 nM. AR453588 hydrochloride shows anti-hyperglycemic activity.
  • HY-N8018
    Leucosceptoside A

    PKC Glucosidase Angiotensin-converting Enzyme (ACE) Metabolic Disease Neurological Disease
    Leucosceptoside A is a phenylethanoid glycoside with anti-hyperglycemic and anti-hypertensive activities. Leucosceptoside A shows inhibitory activity against α-glucosidase and PKCα (IC50 of 19.0 μM).
  • HY-B0225B
    Methyldopa hydrate

    L-(-)-α-Methyldopa hydrate; MK-351 hydrate

    Adrenergic Receptor Cardiovascular Disease Endocrinology
    Methyldopa hydrate (L-(-)-α-Methyldopa hydrate), a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopa hydrate is a prodrug and is metabolized (α-Methylepinephrine) in the central nervous system.
  • HY-107394
    UK 356618

    MMP Cancer Inflammation/Immunology
    UK 356618 (Compound 4j) is a potent and selective inhibitor of matrix metalloprotease-3 (MMP-3) with an IC50 of 5.9 nM. UK 356618 is less potent against MMP-1, MMP-2, MMP-9, MMP-13 and MMP-14 compared with MMP-3.
  • HY-B0225A
    Methyldopa hydrochloride

    L-(-)-α-Methyldopa hydrochloride; MK-351 hydrochloride

    Adrenergic Receptor Cardiovascular Disease Endocrinology
    Methyldopa hydrochloride (L-(-)-α-Methyldopa hydrochloride) hydrochloride, a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopa hydrochloride is a prodrug and is metabolized (α-Methylepinephrine) in the central nervous system.
  • HY-B0225
    Methyldopa

    L-(-)-α-Methyldopa; MK-351

    Adrenergic Receptor Cardiovascular Disease Endocrinology
    Methyldopa (L-(-)-α-Methyldopa), a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopa is a prodrug and is metabolized (α-Methylepinephrine) in the central nervous system.
  • HY-110118
    Edaglitazone

    PPAR
    Edaglitazone is a potent, selective and orally active PPARγ agonist, with EC50s of 35.6 nM and 1053 nM for PPARα and PPARγ, respectively. Edaglitazone displays antiplatelet, antidiabetic and anti-hyperglycemic activity.
  • HY-N3078
    p-Hydroxyphenethyl trans-ferulate

    Glucosidase Endocrinology
    p-Hydroxyphenethyl trans-ferulate has anti-hyperglycemic(yeast α-glucosidaseIC50 19.24 ± 1.73 µmol L-1), antioxidant, and anti-inflammatory activities. p-Hydroxyphenethyl trans-ferulate shows inhibiting cancer preve
  • HY-N1390
    Syringaldehyde

    COX Metabolic Disease Inflammation/Immunology
    Syringaldehyde is a polyphenolic compound belonging to the group of flavonoids and is found in different plant species like Manihot esculenta and Magnolia officinalis. Syringaldehyde moderately inhibits COX-2 activity with an IC50 of 3.5 μg/mL. Anti-hyperglycemic and anti-inflammatory activities.
  • HY-131334
    AMPK activator 4

    AMPK Metabolic Disease
    AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect.
  • HY-W011220
    Ciglitazone

    ADD-3878; U-63287

    PPAR Cancer Cardiovascular Disease
    Ciglitazone is a potent and selective PPARγ agonist (EC50=3 μM). Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone induces apoptosis accompanied by activation of p38 MAPK and nuclear translocation of apoptosis inducing factor (AIF) in opossum kidney (OK) renal epithelial cells.